Engineered therapeutic antibodies with improved effector functions

Cancer Science

Volumn 100, Issue 9, 2009, Pages 1566-1572

  Kubota, Tsuguo ^a   Niwa, Rinpei ^a   Satoh, Mitsuo ^a   Akinaga, Shiro ^a   Shitara, Kenya ^a   Hanai, Nobuo ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY;

ANIMAL; HUMAN; IMMUNOLOGY; NEOPLASM; PROTEIN ENGINEERING; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; HUMANS; NEOPLASMS; PROTEIN ENGINEERING;

EID: 70149086034     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01222.x     Document Type: Review

References (86)

1. Pavlou AK, Belsey MJ. The therapeutic antibodies market to 2008. Eur J Pharm Biopharm 2005; 59: 389-96.
2. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. Monoclonal antibody successes in the clinic. Nature Biotechnol 2005; 23: 1073-8.
3. Oldham RK, Dillman RO. Monoclonal antibodies in cancer therapy: 25 years of progress.J Clin Oncol 2008; 26: 1774-7.
4. Cheson BD. Monoclonal antibody therapy for B-Cell Non-Hodgkin's lymphoma. N Eng J Med 2008; 359: 613-26.
5. Hudis CA. Trastuzumab - Mechanism of action and use in clinical practice. N Eng J Med 2007; 357: 39-51.
6. Peeters M, Price T, Van Laethem JL. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today? Oncologist 2009; 14: 29-39.
7. Marty M, Pivot X. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. Eur J Cancer 2008; 44: 912-20.
8. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
9. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Disc 2006; 5: 835-44.
10. Faivre S, Demetri G, Sargent W, Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Disc 2007; 6: 734-45.
11. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci 1984; 81: 6851-5.
12. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986; 321: 522-5.
13. Tomizuka K, Yoshida H, Uejima H et al. Functional expression and germline atransmission of a human chromosome fragment in chimaeric mice. Nat Genet 1997; 16: 133-43.
14. Mendez MJ, Green LL, Corvalan JRF et al. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat Genet 1997; 15: 146-56.
15. McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
16. Davis TA, Grillo-López AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18: 3135-43.
17. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
18. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
19. Berinstein NL, Grillo-López AJ, White CA et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
20. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-18.
21. Clark MR. IgG effector mechanisms. Chem Immunol 1997; 65: 88-110.
22. Jefferis R, Lund J, Pound JD. IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation. Immunol Rev 1998; 163: 59-76.
23. Jefferis R, Lund J. Interaction sites on human IgG-Fc for FcgammaR: current models. Immunol Lett 2002; 82: 57-65.
24. Rademacher TW, Parekh RB, Dwek RA. Glycobiology. Annu Rev Biochem 1988; 57: 785-838.
25. Mizuochi T, Taniguchi T, Shimizu A, Kobata A. Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. J Immunol 1982; 129: 2016-20.
26. Harada H, Kamei M, Tokumoto Y et al. Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. Anal Biochem 1987; 164: 374-81.
27. Jefferis R. Glycosylation of human IgG antibodies: relevance to therapeutic applications. BioPharm 2002; 14: 19-26.
28. Wright A, Morrison SL. Effect of glycosylation on antibody functions: implications for genetic engineering. Trends Biotechnol 1997; 15: 26-31.
29. Huber R, Deisenhofer J, Colman PM, Matsushima M, Palm W. Crystallographic structure studies of an IgG molecule and an Fc fragment. Nature 1976; 264: 415-20.
30. Radaev S, Motyka S, Fridman WH, Sautes-Fridman C, Sun PD. The structure of a human type III Fcgamma receptor in complex with Fc. J Biol Chem 2001; 276: 16469-77.
31. Harris LJ, Skaletsky E, McPherson A. Crystallographic structure of an intact IgG1 monoclonal antibody. J Mol Biol 1998; 275: 861-72.
32. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 2001; 1: 118-29.
33. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
34. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibodydependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 27: 1533-41.
35. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999; 26: 60-70.
36. Golay J, Cortiana C, Manganini M. The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. Haematologica 2006; 91: 322-30.
37. Golay J, Manganini M, Rambaldi A, Introna M. Effect of alemtuzumab on neoplastic B cells. Haematologica 2004; 89: 1476-83.
38. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940-7.
39. Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754-8.
40. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004; 10: 5650-5.
41. Taylor RJ, Chan SL, Wood A et al. FccRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2008.
42. Louis E, ElGhoul Z, Vermeire S et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004; 19: 511-9.
43. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for FcgRI, FcgRII, FcgRIII, and FcRn and design of IgG1 variants with improved binding to the FcgR. J Biol Chem 2001; 276: 6591-604.
44. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequence of proteins of immunological interest. US Dept. Health and Human Services 1991; 5th edition.
45. Stavenhagen JB, Gorlatov S, Tuaillon N et al. Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization. Adv Enzyme Regul 2008; 48: 152-64.
46. Lazar GA, Dang W, Karki S et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci 2006; 103: 4005-10.
47. Boyd PN, Lines AC, Patel AK. The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. Mol Immunol 1995; 32: 1311-8.
48. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology 1995; 5: 813-22.
49. Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody dependent cellular cytotoxic activity. Nat Biotechnol 1999; 17: 176-80.
50. Davies J, Jiang LY, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FcγRIII. Biotechnol Bioeng 2001; 74: 288-94.
51. Narisimhan S. Control of glycoprotein synthesis. UDP-GlcNAc:glycopeptide beta 4-N-acetylglucosaminyltransferase III, an enzyme in hen oviduct which adds GlcNAc in beta 1-4 linkage to the beta-linked mannose of the trimannosyl core of N-glycosyl oligosaccharides. J Biol Chem 1982; 257: 10235-42.
52. Shinkawa T, Nakamura K, Yamane N et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278: 3466-73.
53. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M et al. Establishment of FUT8 knockout chinese hamster ovary ells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibodydependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87: 614-22.
54. Niwa R, Sakurada M, Kobayashi Y et al. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin Cancer Res 2005; 11: 2327-36.
55. Niwa R, Shoji-Hosaka E, Sakurada M et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-33.
56. Niwa R, Natsume A, Uehara A et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297- linked oligosaccharides. J Immunol Methods 2005; 306: 151-60.
57. Shoji-Hosaka E, Kobayashi Y, Wakitani M et al. Enhanced Fc-dependent cellular cytotoxicity of fc fusion proteins derived from TNF Receptor II and LFA-3 by fucose removal from Asn-linked oligosaccharides. J Biochem 2006; 140: 777-83.
58. Natsume A, Wakitani M, Yamane-Ohnuki N et al. Fucose removal from complextype oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded Fc fusion protein comprising an single-chain antibody linked the antibody constant region. J Immunol Methods 2005; 306: 93-103.
59. Satoh M, Iida S, Shitara K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther 2006; 6: 1161-73.
60. Javaud C, Dupuy F, Maftah A et al. Ancestral exonic organization of FUT8, the gene encoding the alpha6-fucosyltransferase, reveals successive peptide domains which suggest a particular three-dimensional core structure for the alpha6-fucosyltransferase family. Mol Biol Evol 2000; 17: 1661-72.
61. Yamane-Ohnuki N, Yamano K, Satoh M. Biallelic gene knockouts in Chinese hamster ovary cells. Methods Mol Biol 2008; 435: 1-16.
62. Niwa R, Hatanaka S, Shoji-Hosaka E et al. Enhancement of the antibodydependent cellular cytotoxicity of low-fucose IgG1 is independent of FcgammaRIIIa functional polymorphism. Clin Cancer Res 2004; 10: 6248-55.
63. Iida S, Misaka H, Inoue M et al. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibodydependent cellular cytotoxicity through its high binding to FcγRIIIa. Clin Cancer Res 2006; 12: 2879-87.
64. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Cuur Opin Invest Drugs 2008; 9: 1206-15.
65. Bowles JA, Wang SY, Link BK et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006; 108: 2648-54.
66. Salles GA, Morschhauser F, Cartron G et al. A phase I/II study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. 50th American Society of Hematology Annual Meeting 2008; #234.
67. Ishida T, Utsunomiya A, Iida S et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625-34.
68. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 1139-46.
69. Yamamoto K, Tobinai K, Utsunomiya A et al. Phase I study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patient (Pts) with adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL): updated results. 50th American Society of Hematology Annual Meeting 2008; Poster: #1007.
70. Anolik JH, Campbell D, Felgar RE et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48: 455-9.
71. A MEDI-563, and anti-interleukin-5 receptor antibody, is well tolerated and induces reversible blood eosinopenia in mild asthma in a Phase I trial. MICP- 158. Proceedings of the 5th Biennial Symposium of the International Eosinophil Society; 18-22 July 2007, Snowbird, UT, USA, 2007.
72. Gaetano ND, Cittera E, Nota R et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-7.
73. Kennedy AD, Beum PV, Solga MD et al. Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymophocytic Leukemia. J Immunol 2004; 172: 3280-8.
74. Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486-95.
75. Teeling JL, Mackus WJM, Wiegman LJJM et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006; 177: 362-71.
76. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111: 1094-100.
77. Golay J, Zaffaroni L, Vaccari T et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95: 3900-8.
78. Treon SP, Mitsiades C, Mitsiades N et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 166: 2571-5.
79. Terui Y, Sakurai T, Mishima Y et al. Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complementdependent cytotoxicity with rituximab. Cancer Sci 2006; 97: 72-9.
80. Idusogie EE, Wong PY, Presta LG et al. Engineered antibodies with increased activity to recruit complement. J Immunol 2001; 166: 2571-5.
81. Dall'Acqua WF, Cook KE, Damschroder MM, Woods RM, Wu H. Modulation of the effector functions of a human IgG1 through engineering of its hinge region. J Immunol 2006; 177: 1129-38.
82. Natsume A, In M, Takamura H et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68: 3863-72.
83. Raghavan M, Bonagura VR, Morrison SL, Bjorkman PJ. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants. Biochemistry 1995; 34: 14649-57.
84. Ghetie V, Popov S, Borvak J et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nature Biotechnol 1997; 15: 637-40.
85. Hinton PR, Johlfs MG, Xiong JM et al. Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 2004; 279: 6213-6.
86. Dall'Acqua WF, Kiener PA, Wu H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 2006; 281: 23514-24.